The Day "Weight Loss Drugs" Become an Adjunct in Cancer Treatment: The Emerging Potential of GLP-1 Drugs in Metastasis Inhibition

GLP-1 receptor agonists, known for treating diabetes and obesity, are suddenly gaining attention in the world of cancer medicine.

GLP-1 receptor agonists are drugs that mimic the action of the hormone GLP-1 in the body. They help regulate blood sugar levels, suppress appetite, and slow the movement of stomach contents. As a result, they have been used not only for treating type 2 diabetes but also as medications for obesity. Known by names such as semaglutide, liraglutide, and tirzepatide, they are often referred to as "weight loss drugs" or "obesity treatments."

However, at ASCO 2026, the annual meeting of the American Society of Clinical Oncology, a series of studies were presented suggesting that this group of drugs might influence cancer risk, progression, metastasis, and mortality. Of particular interest was a report that the use of GLP-1 drugs was associated with reduced metastatic progression in patients already diagnosed with cancer.

Of course, this does not mean that "GLP-1 drugs cure cancer." What has been shown so far is merely a correlation. The studies are primarily observational or retrospective analyses using clinical databases, and it has not been proven that the drugs themselves directly halted cancer progression.

Nevertheless, the medical community, patient groups, investors, and general social media users have reacted because this topic goes beyond mere new drug news. Obesity, diabetes, chronic inflammation, immunity, and cancer—major themes of modern medicine—are beginning to connect through a single group of drugs.

What Are GLP-1 Drugs?

GLP-1 is a type of hormone secreted from the small intestine after eating, which promotes insulin secretion and works to lower blood sugar levels. It also affects the brain's appetite center and gastrointestinal movement, enhancing the feeling of fullness.

GLP-1 receptor agonists utilize this action as a drug. Originally introduced as a treatment for type 2 diabetes, early drugs primarily aimed at blood sugar control. Recently, drugs with significant weight loss effects have been developed, rapidly increasing their presence in the field of obesity treatment.

Currently, the scope of research on GLP-1 drugs has expanded significantly, including cardiovascular risk reduction, sleep apnea, kidney disease, fatty liver, alcohol dependence, and dementia. Newly added to this is the relationship with cancer.

The "Metastasis Inhibition" Signal Presented at ASCO 2026

One of the studies that drew attention was an analysis by Dr. Mark David Orland and colleagues at the Cleveland Clinic. The study used a large medical database called TriNetX to compare cancer patients in stages I to III who used GLP-1 receptor agonists with those who used another diabetes drug, DPP-4 inhibitors.

The subjects were multiple solid cancers associated with obesity, including breast cancer, prostate cancer, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, renal cell carcinoma, and pancreatic cancer. The analysis showed a tendency for lower progression rates to stage IV, which involves metastasis, in the patient group using GLP-1 drugs.

Statistically significant differences were particularly shown in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma. In non-small cell lung cancer, about 10% of the GLP-1 drug user group progressed to stage IV, compared to about 22% in the comparison group. For breast cancer, it was about 10% versus 20%, for colorectal cancer about 13% versus 22%, and for hepatocellular carcinoma about 19% versus 28%.

These numbers might seem like a very large effect. However, it is important to note that this is not a randomized controlled trial. Various factors such as patient background, medical access, concomitant treatments, lifestyle, degree of obesity, and diabetes management could have influenced the results.

The research team is not concluding that GLP-1 drugs directly suppressed cancer metastasis. Rather, this result should be seen as a "strong signal worth verifying in prospective trials."

Is It Acting Directly or Regulating the Whole Body?

The biggest issue in the relationship between GLP-1 drugs and cancer is the nature of their action.

One possibility is the indirect effect of weight loss. Obesity is associated with the risk of several cancers, such as postmenopausal breast cancer, colorectal cancer, liver cancer, and endometrial cancer. Visceral fat can cause chronic inflammation and insulin resistance, potentially creating an environment conducive to cancer cell proliferation. If GLP-1 drugs lead to weight loss, these risk factors might improve, thereby naturally explaining the suppression of cancer onset and progression.

However, researchers are also focusing on other possibilities. GLP-1 drugs are thought to have anti-inflammatory effects, improve insulin signaling, and affect immune responses. Cancer is not just a problem of tumor cells but is strongly influenced by the surrounding inflammation, blood vessels, immunity, and metabolic environment. By altering these environments, GLP-1 drugs might be affecting cancer progression.

Furthermore, the expression of GLP-1 receptors in tumors was also highlighted in the study. Analysis results showed that tumors with high GLP-1 receptor expression had better overall survival rates, suggesting that GLP-1 signaling might have some relationship with tumor characteristics and progression.

However, this is still at the hypothesis stage. Whether high GLP-1 receptor expression leads to better prognosis, or whether tumors with good prognosis happen to have such characteristics, and how the drug acts there, need to be clarified in future basic research and clinical trials.

Rising Expectations for Breast Cancer Prevention

At ASCO 2026, research on not only cancer progression but also prevention was reported. A study from the University of Pennsylvania analyzed the relationship between GLP-1 drug use and breast cancer risk in over 110,000 women aged 45 to 80.

The results showed a tendency for lower odds of developing breast cancer in women who used GLP-1 drugs compared to those who did not. Reports introduced this as about a 30% reduction in risk.

Breast cancer is one of the most diagnosed cancers worldwide, and improving prevention strategies is highly significant. Obesity, especially postmenopausal obesity, is associated with breast cancer risk, and the possibility that weight loss could lead to preventive effects has been considered before. If GLP-1 drugs also affect inflammation and metabolic pathways beyond weight, research into their use as cancer preventive drugs might progress.

However, the idea of using GLP-1 drugs for prevention is still a discussion for the future. The drugs have side effects, are expensive, and have challenges with long-term use. To administer them for preventive purposes to healthy individuals, it must be strictly proven that the benefits clearly outweigh the risks.

Mixed Reactions on Social Media

The news elicited various reactions on social media.

In the Reddit community that deals with future technology and medical news, there was an optimistic voice saying, "If it started as a diabetes drug, became an obesity treatment, and now has the potential to become an adjunct in cancer treatment, it's a major shift." Posts focusing on the possibility of effects through inflammation and immune modulation, not just weight loss, were prominent.

On the other hand, there were many cautious voices in medical discussions. Comments included, "It's an observational study, and causality is not proven," "Selection bias or differences in health status might have influenced the results," and "If it truly has an effect, a randomized controlled trial is needed." The impression is that more expert users emphasize the limitations of the study design over the impact of headlines.

From general users, there were positive reactions like "If it also relates to cancer prevention, it's great news," and "If the risk of obesity-related cancer decreases, it makes sense." GLP-1 drugs are already known for their multifaceted effects, such as weight loss, blood sugar management, and cardiovascular risk reduction, and there is surprise at "yet another new effect emerging."

On the other hand, concerns were raised about "What about side effects?" "It's not a drug that anyone can easily use," and "Only those who can afford expensive drugs will benefit." In fact, GLP-1 drugs are well-known for side effects such as nausea, diarrhea, constipation, and gastrointestinal symptoms. On social media, users and those with experience share their stories, discussing lifestyle issues that medical papers might not capture.

Additionally, stories of GLP-1 drug side effects from celebrities have also garnered attention. Whether for weight loss or not, the use of GLP-1 drugs requires appropriate judgment by a physician, and there is a growing perception that they should not be used lightly just because they are trending on social media.

From "Weight Loss Drugs" to "Metabolic Regulating Drugs"

GLP-1 drugs are often referred to as "weight loss drugs" in general. However, the cancer research presented this time suggests that it might be insufficient to view this group of drugs merely as weight loss medications.

Obesity is not just a state of being overweight but is linked to chronic inflammation, hormonal environment, lipid metabolism, insulin resistance, immune function, and other biological states of the whole body. Cancer, too, is a disease that progresses under the influence of the body's internal environment, not just genetic mutations of cells.

In that sense, it is natural for GLP-1 drugs to attract attention in the cancer field. When viewed as drugs that change the metabolic environment rather than just weight loss drugs, connections with a wide range of diseases such as diabetes, cardiovascular disease, fatty liver, dementia, and cancer become apparent.

Of course, the greater the expectations, the higher the risk of overestimation. GLP-1 drugs are not a panacea. They do not work for all cancers, nor are they suitable for all patients. Even in this study, results varied by cancer type, and there were parts where no statistically clear differences were shown, such as in renal cancer and pancreatic cancer.

What Is Needed Next Is a Trial to Confirm "Does It Really Work?"

The next step is a prospective randomized controlled trial. It is necessary to compare groups of cancer patients who add GLP-1 drugs to standard treatment with those who do not, and rigorously evaluate metastasis, recurrence, survival, side effects, and quality of life.

In doing so, it will also be important to determine which patients are more likely to benefit. The effect may vary depending on factors such as the presence or absence of obesity, diabetes, insulin resistance, inflammation markers, GLP-1 receptor expression, cancer type, stage, and treatment content.

If the effect is confirmed in specific patient groups, GLP-1 drugs might be positioned not as cancer treatments themselves but as supportive options that aid treatment. For example, improving metabolic status, reducing inflammation, and lowering the risk of recurrence or metastasis while receiving standard treatment.

This is a different concept from traditional anticancer drugs or immunotherapy. Instead of directly attacking cancer cells, it creates a body environment where cancer is less likely to progress. This idea of "controlling cancer through metabolism" might become a research theme in the future.

A Realistic Perspective for Patients

It is natural for cancer patients and their families to wonder, "Should we use GLP-1 drugs?" after seeing this news. However, at this point, it is not the stage to seek use based on self-judgment.

GLP-1 drugs have indications, and it is necessary to consider the state of diabetes or obesity, medical history, concomitant medications, gastrointestinal symptoms, pancreatitis risk, gallbladder disease, nutritional status, and more. In cancer patients undergoing treatment, weight loss is not always desirable. For those whose appetite has decreased due to treatment, muscle mass has decreased, or nutritional status has worsened, a drug that further suppresses appetite might work unfavorably.

In other words, GLP-1 drugs are not "used because they seem good for cancer." They are medications used when medically necessary for the treatment of diabetes or obesity, in consultation with a primary care physician. As for their effects in the cancer field, clinical trials in the future need to be awaited.

Hopeful but Not to Be Jumped On

The relationship between GLP-1 drugs and cancer will likely see further research in the coming years. The presentation at ASCO 2026 seems to be one of its major starting points.

There are many promising aspects. Consistent signals were seen across multiple cancer types. Associations were shown with clinically important indicators such as reduced metastatic progression and mortality. There is a possibility that cannot be fully explained by weight loss alone. And since it is a drug group already widely used, there is relatively more accumulation of safety and usage experience.

On the other hand, the reasons for being cautious are also clear. Many studies are observational, and causality is unknown. Differences between drugs have not been sufficiently distinguished. The duration of use, dosage, start time, and combination with cancer treatment have not been organized yet. As it becomes a topic on social media, expectations alone may lead to misunderstandings and overuse.

A simple headline like "Weight Loss Drugs Prevent Cancer" misses the essence of this research. More accurately, it is "Drugs that act on metabolism and inflammation may also affect the cancer progression environment."

GLP-1 drugs are expanding their role from diabetes treatments to obesity treatments, and now to new candidates in cancer research. However, to truly utilize their potential in medicine, it is necessary to connect expectations to calm verification.

This study poses questions rather than answers. Is cancer progression influenced not only by the tumor but also by the patient's overall metabolic state? If so, the future of cancer treatment might expand not only to attacking tumors but also to improving the internal environment.

Source URL

Le Journal de Saône-et-Loire / Destination Santé "Les médicaments anti-obésité, une piste contre le cancer ?"
An article introducing the ASCO 2026 presentation on GLP-1 receptor agonists and cancer progression. The main basis for the structure of this article.
https://www.lejsl.com/magazine-sante/2026/06/08/les-medicaments-anti-obesite-une-piste-contre-le-cancer

ASCO Post: Overview of Research on GLP-1 Receptor Agonists and Metastatic Progression of Obesity-Related Cancers
Verification of the analysis of 12,112 people using TriNetX, target cancer types, stage IV progression rates, and study limitations.
https://ascopost.com/news/may-2026/glp-1-ras-may-reduce-metastatic-progression-in-certain-obesity-related-cancers/

Reuters: Overview of Studies on GLP-1 Drugs and Multiple Cancer Types Presented at ASCO 202